OTLK
OUTLOOK THERAPEUTICS INCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$181.28M
P/E Ratio
—
EPS
$-1.13
Beta
0.98
52W High
$3.39
52W Low
$0.16
50-Day MA
$0.41
200-Day MA
$0.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.85
PEG Ratio
—
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Fundamentals
| Revenue (TTM) | 333,140 |
| Gross Profit (TTM) | $-1.20M |
| EBITDA | $-60.45M |
| Operating Margin | -11007.00% |
| Return on Equity | -3.65% |
| Return on Assets | -184.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-0.28 |
| Price-to-Book | 38.42 |
| Price-to-Sales (TTM) | 442.61 |
| EV/Revenue | 555.66 |
| EV/EBITDA | -4.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 658.00% |
| Shares Outstanding | $148.59M |
| Float | $96.40M |
| % Insiders | 17.42% |
| % Institutions | 6.92% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Analyst Ratings
Consensus ($5.50 target)
2
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026